

## Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.

Tel. : (91-22) 4324 4324

Fax : (91-22) 4324 4343

Website: [www.sunpharma.com](http://www.sunpharma.com)

Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)

CIN: L24230GJ1993PLC019050



26 September 2026

**National Stock Exchange of India Limited**  
**Scrip Symbol: SUNPHARMA**

**BSE Limited**  
**Scrip Code: 524715**

### **Intimation under Regulation 30 and Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Receipt of approval of the shareholders for reclassification of shareholder category**

---

Further to our intimations letter dated [14 May 2026](#), [22 May 2026](#), [26 May 2026](#), [06 August 2026](#), and [25 August 2026](#), this is to inform that the shareholders of the Company, on 26 September 2026, have approved reclassification of the persons referred to in our intimation dated 14 May 2026 from the ‘Promoter Group’ category to the ‘Public’ category in accordance with Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”).

The effect of the aforesaid reclassification shall be reflected in the subsequent quarterly shareholding patterns filed by the Company with the Stock Exchanges in accordance with the applicable provisions of the SEBI Listing Regulations.

This intimation is being made in compliance with the provisions of the SEBI Listing Regulations.

**For Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)

**Company Secretary and Compliance Officer**

ICSI Membership No.: A23983